Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360 CDx and Guardant360 TissueNext as Companion Diagnostics for Positive Non-Small Cell Lung Cancer
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360 CDx and Guardant360 TissueNext as Companion Diagnostics for Positive Non-Small Cell Lung Cancer
Guardant Health 和 anHeart Therapeutics 宣布合作开发 Guardant360 CDx 和 Guardant360 TissueNext 作为非小细胞肺癌阳性的伴随诊断工具
Collaboration is Guardant Health's first to explore both tissue- and blood-based assays as companion diagnostics (CDx). Taletrectinib is an investigational ROS1 inhibitor for the treatment of adult patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
协作是Guardant Health第一个探索组织和血液分析作为伴随诊断(CDX)的公司。̂Taletrectinib是一种研究中的ROS1I抑制剂,用于治疗晚期或转移性ROS1阳性非小细胞肺癌(NSCLC)。